Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: Involvement of FOXO3a

Cell Cycle

Volumn 11, Issue 13, 2012, Pages 2467-2475

  Buontempo, Francesca ^a   Chiarini, Francesca ^a   Bressanin, Daniela ^b   Tabellini, Giovanna ^c   Melchionda, Fraia ^b   Pession, Andrea ^b   Fini, Milena ^a   Neri, Luca M ^d   McCubrey, James A ^e   Martelli, Alberto M ^a,b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Apoptosis; BMS 345541; Cell cycle; FOXO3a; IKK; NF B; T cell acute lymphoblastic leukemia

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NOTCH1 RECEPTOR; PROTEIN KINASE B; PROTEIN P21; TRANSCRIPTION FACTOR FKHRL1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; ENZYME INHIBITION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LEUKEMIA CELL LINE; PROTEIN EXPRESSION;

EID: 84863808495     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20859     Document Type: Article

References (36)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371:1030-43; PMID:18358930; http://dx.doi.org/10.1016/S0140-6736(08)60457-2.
2. Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev 2011; 25:83-90; PMID:20965628; http://dx.doi.org/10.1016/j.blre.2010.09.004.
3. Kox C, Zimmermann M, Stanulla M, Leible S, Schrappe M, Ludwig WD, et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 2010; 24:2005-13; PMID:20944675; http://dx.doi.org/10.1038/leu.2010.203.
4. Indraccolo S, Minuzzo S, Masiero M, Amadori A. Liganddriven activation of the notch pathway in T-ALL and solid tumors: why Not(ch)? Cell Cycle 2010; 9:80-5; PMID:20016278; http://dx.doi.org/10.4161/cc.9.1.10346.
5. Koch U, Radtke F. Notch in T-ALL: new players in a complex disease. Trends Immunol 2011; 32:434-42; PMID:21775206; http://dx.doi.org/10.1016/j.it. 2011.06.005.
6. Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med 2011; 208:1931-5; PMID:21948802; http://dx.doi.org/10.1084/jem.20111855.
7. Borggrefe T, Liefke R. Fine-tuning of the intracellular canonical Notch signaling pathway. Cell Cycle 2012; 11:264-76; PMID:22223095; http://dx.doi.org/10.4161/cc.11.2.18995.
8. Weng AP, Ferrando AA, Lee W, Morris JP, 4th, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306:269-71; PMID:15472075; http://dx.doi.org/10.1126/science.1102160.
9. Screpanti I, Bellavia D, Campese AF, Frati L, Gulino A. Notch, a unifying target in T-cell acute lymphoblastic leukemia? Trends Mol Med 2003; 9:30-5; PMID:12524208; http://dx.doi.org/10.1016/S1471-4914(02)00003-5.
10. Shin HM, Minter LM, Cho OH, Gottipati S, Fauq AH, Golde TE, et al. Notch1 augments NFkappaB activity by facilitating its nuclear retention. EMBO J 2006; 25:129-38; PMID:16319921; http://dx.doi.org/10.1038/sj.emboj.7600902.
11. Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F, et al. Targeting the NFkappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007; 13:70-7; PMID:17173050; http://dx.doi.org/10.1038/nm1524.
12. Karin M. Nuclear factorkappaB in cancer development and progression. Nature 2006; 441:431-6; PMID:16724054; http://dx.doi.org/10.1038/nature04870.
13. Demchenko YN, Kuehl WM. A critical role for the NFκB pathway in multiple myeloma. Oncotarget 2010; 1:59-68; PMID:20890394.
14. Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL. The NFκB pathway: a therapeutic target in glioblastoma. Oncotarget 2011; 2:646-53; PMID:21896960.
15. Vallabhapurapu S, Karin M. Regulation and function of NFkappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27:693-733; PMID:19302050; http://dx.doi.org/10.1146/annurev.immunol.021908.132641.
16. Kornblau SM, Singh N, Qiu Y, Chen W, Zhang N, Coombes KR. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res 2010; 16:1865-74; PMID:20215543; http://dx.doi.org/10.1158/ 1078-0432.CCR-09-2551.
17. Chapuis N, Park S, Leotoing L, Tamburini J, Verdier F, Bardet V, et al. IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia. Blood 2010; 116:4240-50; PMID:20671123; http://dx.doi.org/10.1182/blood-2009-12-260711.
18. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5:297-309; PMID:15803156; http://dx.doi.org/10.1038/nrc1588.
19. Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, et al. BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NFκB-dependent transcription in mice. J Biol Chem 2003; 278:1450-6; PMID:12403772; http://dx.doi.org/10.1074/jbc.M209677200.
20. Herrmann O, Baumann B, de Lorenzi R, Muhammad S, Zhang W, Kleesiek J, et al. IKK mediates ischemia-induced neuronal death. Nat Med 2005; 11:1322-9; PMID:16286924; http://dx.doi.org/10.1038/nm1323.
21. Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 2006; 12:950-60; PMID:16467110; http://dx.doi.org/10.1158/1078-0432.CCR-05-1220.
22. Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, Philip P, et al. Targeting NFkappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 2005; 105:804-11; PMID:15454494; http://dx.doi.org/10.1182/blood-2004-04-1463.
23. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008; 10:138-48; PMID:18204439; http://dx.doi.org/10.1038/ncb1676.
24. Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010; 19:1355-66; PMID:20846000; http://dx.doi.org/10.1517/13543784.2010.520701.
25. Riz I, Zweier-Renn LA, Toma I, Hawley TS, Hawley RG. Apoptotic role of IKK in T-ALL therapeutic response. Mol Cancer Res 2011; 9:979-84; PMID:21730014; http://dx.doi.org/10.1158/1541-7786.MCR-11-0109.
26. Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, Guiu J, et al. The Notch/Hes1 pathway sustains NFκB activation through CYLD repression in T cell leukemia. Cancer Cell 2010; 18:268-81; PMID:20832754; http://dx.doi.org/10.1016/j.ccr.2010.08.006.
27. Cleaver AL, Beesley AH, Firth MJ, Sturges NC, O'Leary RA, Hunger SP, et al. Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study. Mol Cancer 2010; 9:105; PMID:20459861; http://dx.doi.org/10.1186/1476-4598-9-105.
28. Nakanishi C, Toi M. Nuclear factorkappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5:297-309; PMID:15803156; http://dx.doi.org/10.1038/nrc1588.
29. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117:225-37; PMID:15084260; http://dx.doi.org/10.1016/S0092-8674(04)00302-2.
30. Myatt SS, Lam EW. The emerging roles of fork-head box (Fox) proteins in cancer. Nat Rev Cancer 2007; 7:847-59; PMID:17943136; http://dx.doi.org/10.1038/ nrc2223.
31. Steelman LS, Martelli AM, Nicoletti F, McCubrey JA. Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity. Oncotarget 2011; 2:109-12; PMID:21487160.
32. Mitkevich VA, Petrushanko IY, Spirin PV, Fedorova TV, Kretova OV, Tchurikov NA, et al. Sensitivity of acute myeloid leukemia Kasumi-1 cells to binase toxic action depends on the expression of KIT and AML1-ETO oncogenes. Cell Cycle 2011; 10:4090-7; PMID:22101339; http://dx.doi.org/10.4161/cc.10.23. 18210.
33. Jung AS, Kaushansky A, Macbeath G, Kaushansky K. Tensin2 is a novel mediator in thrombopoietin (TPO)-induced cellular proliferation by promoting Akt signaling. Cell Cycle 2011; 10:1838-44; PMID:21527831; http://dx.doi.org/10. 4161/cc.10.11.15776.
34. Dufies M, Jacquel A, Robert G, Cluzeau T, Puissant A, Fenouille N, et al. Mechanism of action of the multikinase inhibitor Foretinib. Cell Cycle 2011; 10:4138- 48; PMID:22101270; http://dx.doi.org/10.4161/cc.10.23.18323.
35. Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, Domany E, et al. Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle 2011; 10:4330-40; PMID:22134238; http://dx.doi.org/10.4161/cc.10.24.18682.
36. Fraser M, Harding SM, Zhao H, Coackley C, Durocher D, Bristow RG. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle 2011; 10:2218-32; PMID:21623170; http://dx.doi.org/10.4161/cc.10.13. 16305.